<u>INTM/019 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Quinn Tang et al.

Application No. : 10/588,602 Confirmation No. : 7130

Filed: August 7, 2006

For : RNAi THERAPEUTICS FOR TREATMENT OF EYE

NEOVASCULARIZATION DISEASES

Group Art Unit : Not Yet Assigned

Examiner : Not Yet Assigned

New York, New York

July 10, 2008

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

PRELIMINARY AMENDMENT AND RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Sir:

This responds to the June 10, 2008 Notification of Defective Response ("Notification"; copy enclosed) in the above-identified application. A response is due by July 10, 2008. Thus, this response is timely filed.

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

The Notification states that the sequence listing submitted with applicants' June

13, 2007 Response does not comply with the requirements of 37 C.F.R. § 1.822 and/or § 1.823

as indicated in the marked-up Raw Sequence Listing (copy enclosed). Specifically, the marked-

up Raw Sequence Listing indicates that a cumulative nucleotide total must be inserted at the

right margin.

Applicants hereby submit Substitute paper and CRF copies of the Sequence

Listing, in accordance with the requirements of 37 C.F.R. §§ 1.822 and 1.823 in which

cumulative nucleotide totals have been inserted at the right margin. Applicants also submit

herewith a Statement Under 37 C.F.R. §§ 1.821 and 1.825, verifying that the Substitute paper

copy of the Sequence Listing and the Substitute CRF copy of the Sequence Listing filed herewith

are identical and do not include new matter. Applicants have additionally amended the

specification to replace the paper and CRF copies of the Substitute Sequence Listing, filed on

June 13, 2007, with the paper and CRF copies of the Substitute Sequence Listing filed herewith.

None of these amendments adds new matter.

No fee is believed to be due for the filing of this Response. However, the

Director is authorized to charge any fees that may be due to Deposit Account No. 06-1075, Order

No. 104825-0019. A duplicate copy of this Response is enclosed herewith.

3

Application No: 10/588,602

Preliminary Amendment and Response dated July 10, 2008 In Response to June 10, 2008 Notification of Defective Response

Applicants request entry of the amendments and early allowance of the pending

claims.

Respectfully submitted,

Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

Alla Brukman (Reg. No. 61,254)

Agent for Applicants

ROPES & GRAY LLP

Customer No. 1473

1211 Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000 Fax: (212) 596-9090